Table I.
Background characteristics of patients receiving continuous treatment with pranlukast dry syrup (group A) and those receiving add-on treatment at the onset of pollinosis (group B).
| Characteristics | Group A | Group B | P-value |
|---|---|---|---|
| Patients (male/female) | 20 (11/9) | 20 (15/5) | |
| Age (years) | 5.3±0.29 | 8.7±0.56 | <0.01 |
| Complications | |||
| Asthmaa | 3/6/11/0 | 8/3/8/1 | NS |
| Perennial allergic rhinitis | 3 | 6 | NS |
| Allergic conjunctivitis | 2 | 5 | NS |
| Atopic dermatitis | 5 | 9 | NS |
| Others | 1 | 1 | NS |
a
Intermittent to persistent/mild to persistent/moderate to persistent/severe. Data were analyzed using paired t-tests and chi-square tests and are presented as the mean ± standard error of the mean where appropriate. NS, not significant.